Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.
CRCT, Université de Toulouse, CNRS ERL 5294, Inserm U1037, Toulouse, France.
S
S
Betrian
CRCT, Université de Toulouse, CNRS ERL 5294, Inserm U1037, Toulouse, France.|Department of Haematology, Institut Universitaire du Cancer, Toulouse, France.
L
L
Ysebaert
Boehringer Ingelheim RCV GmbH & Co KG, Wien, Austria.
K H
KH
Heider
Institut Universitaire du Cancer, Bureau d'études cliniques, Toulouse, France.
J P
JP
Delord
CRCT, Université de Toulouse, CNRS ERL 5294, Inserm U1037, Toulouse, France.
J J
JJ
Fournié
CRCT, Université de Toulouse, CNRS ERL 5294, Inserm U1037, Toulouse, France.
A
A
Quillet-Mary
D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology* / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology*; D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004357:Drug Synergism; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D011687:Purines / Q000008:administration & dosage* / Q000494:pharmacology; D052999:Quinazolinones / Q000008:administration & dosage* / Q000494:pharmacology; D012008:Recurrence; D059470:Tetraspanins / Q000276:immunology*; D016896:Treatment Outcome; D059016:Tumor Microenvironment / Q000187:drug effects
D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm; D000074322:Antineoplastic Agents, Immunological; C000626798:BI 836826; C059071:CD37 protein, human; D011687:Purines; D052999:Quinazolinones; D059470:Tetraspanins; C552946:idelalisib